Search

Your search keyword '"Onozawa, Masahiro"' showing total 508 results
Start Over Author "Onozawa, Masahiro" Search Limiters Full Text
508 results on '"Onozawa, Masahiro"'

1. FLT3 inhibitors and hematopoietic cell transplantation prolong survival in patients with FLT3-ITD-positive AML

Author

Matsukawa, Toshihiro, Onozawa, Masahiro, Kondo, Takeshi, Kanaya, Minoru, Hidaka, Daisuke, Ota, Shuichi, Mori, Akio, Shigematsu, Akio, Miyagishima, Takuto, Kakinoki, Yasutaka, Hashiguchi, Junichi, Yamamoto, Satoshi, Yamamoto, Masayo, Wakasa, Kentaro, Takahata, Mutsumi, Ishihara, Toshimichi, Haseyama, Yoshihito, Fujimi, Akihito, Igarashi, Tetsuya, Sarashina, Takehiro, Iyama, Satoshi, Kobayashi, Ryoji, Sakai, Hajime, Fujimoto, Katsuya, Inamura, Junki, Kanisawa, Yuji, Hirabayashi, Shinsuke, Endo, Tomoyuki, Hashimoto, Daigo, and Teshima, Takanori

Published
2024
Full Text
View/download PDF

3. Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy.

Author

Martinelli, Giovanni, Neubauer, Andreas, Sierra, Jorge, Montesinos, Pau, Recher, Christian, Yoon, Sung-Soo, Maeda, Yoshinobu, Hosono, Naoko, Onozawa, Masahiro, Kato, Takayasu, Kim, Hee-Je, Hasabou, Nahla, Nuthethi, Rishita, Tiu, Ramon, Levis, Mark, Perl, Alexander, Larson, Richard, Podoltsev, Nikolai, Strickland, Stephen, Wang, Eunice, Atallah, Ehab, and Schiller, Gary

Subjects
Acute myelogenous leukemia, FLT3 inhibitor, FLT3 mutation, Hematopoietic stem cell transplantation, Post-transplantation maintenance therapy, Adult, Humans, fms-Like Tyrosine Kinase 3, Leukemia, Myeloid, Acute, Aniline Compounds, Recurrence
Abstract

The fms-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib improved the survival of patients with relapsed or refractory (R/R) FLT3-mutated acute myelogenous leukemia (AML) in the phase 3 ADMIRAL trial. In this study, we assessed survival and relapse rates of patients in the ADMIRAL trial who underwent hematopoietic stem cell transplantation (HSCT), as well as safety outcomes in patients who received post-transplantation gilteritinib maintenance therapy. ADMIRAL was a global phase 3 randomized controlled trial that enrolled adult patients with FLT3-mutated R/R AML. Patients with R/R AML who harbored FLT3 internal tandem duplication mutations in the juxtamembrane domain or D835/I836 point mutations in the tyrosine kinase domain were randomized (2:1) to gilteritinib (120 mg/day) or to preselected high- or low-intensity salvage chemotherapy (1 or 2 cycles). Patients in the gilteritinib arm who proceeded to HSCT could receive post-transplantation gilteritinib maintenance therapy if they were within 30 to 90 days post-transplantation and had achieved composite complete remission (CRc) with successful engraftment and no post-transplantation complications. Adverse events (AEs) during HSCT were recorded in the gilteritinib arm only. Survival outcomes and the cumulative incidence of relapse were assessed in patients who underwent HSCT during the trial. Treatment-emergent AEs were evaluated in patients who restarted gilteritinib as post-transplantation maintenance therapy. Patients in the gilteritinib arm underwent HSCT more frequently than those in the chemotherapy arm (26% [n = 64] versus 15% [n = 19]). For all transplantation recipients, 12- and 24-month overall survival (OS) rates were 68% and 47%, respectively. Despite a trend toward longer OS after pretransplantation CRc, post-transplantation survival was comparable in the 2 arms. Patients who resumed gilteritinib after HSCT had a low relapse rate after pretransplantation CRc (20%) or CR (0%). The most common AEs observed with post-transplantation gilteritinib therapy were increased alanine aminotransferase level (45%), pyrexia (43%), and diarrhea (40%); grade ≥3 AEs were related primarily to myelosuppression. The incidences of grade ≥III acute graft-versus-host disease and related mortality were low. Post-transplantation survival was similar across the 2 study arms in the ADMIRAL trial, but higher remission rates with gilteritinib facilitated receipt of HSCT. Gilteritinib as post-transplantation maintenance therapy had a stable safety and tolerability profile and was associated with low relapse rates. Taken together, these data support a preference for bridging therapy with gilteritinib over chemotherapy in transplantation-eligible patients.

Published
2023

5. Dominant-negative type of IKZF1 deletion showed a favorable prognosis in adult B-cell acute lymphoblastic leukemia

Author

Kimura, Hiroyuki, Onozawa, Masahiro, Yoshida, Shota, Miyashita, Naoki, Yokoyama, Shota, Matsukawa, Toshihiro, Hirabayashi, Shinsuke, Goto, Hideki, Endo, Tomoyuki, Oguri, Satoshi, Fujisawa, Shinichi, Mori, Akio, Kondo, Takeshi, Hidaka, Daisuke, Okada, Kohei, Ota, Shuichi, Kakinoki, Yasutaka, Tsutsumi, Yutaka, Yamamoto, Satoshi, Miyagishima, Takuto, Hashiguchi, Junichi, Nagashima, Takahiro, Ibata, Makoto, Wakasa, Kentaro, Haseyama, Yoshihito, Fujimoto, Katsuya, Ishihara, Toshimichi, Sakai, Hajime, and Teshima, Takanori

Published
2023
Full Text
View/download PDF

7. Calcineurin inhibitor inhibits tolerance induction by suppressing terminal exhaustion of donor T cells after allo-HCT

Author

Senjo, Hajime, Harada, Shinpei, Kubota, Shimpei I., Tanaka, Yuki, Tateno, Takahiro, Zhang, Zixuan, Okada, Satomi, Chen, Xuanzhong, Kikuchi, Ryo, Miyashita, Naoki, Onozawa, Masahiro, Goto, Hideki, Endo, Tomoyuki, Hasegawa, Yuta, Ohigashi, Hiroyuki, Ara, Takahide, Hasegawa, Yoshinori, Murakami, Masaaki, Teshima, Takanori, and Hashimoto, Daigo

Published
2023
Full Text
View/download PDF

8. Immunogenicity of three versus four doses of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in allogeneic haematopoietic stem cell transplantation recipients: a multicentre, randomized controlled trial

Author

Okinaka, Keiji, Akeda, Yukihiro, Inamoto, Yoshihiro, Fuji, Shigeo, Ito, Ayumu, Tanaka, Takashi, Kurosawa, Saiko, Kim, Sung-Won, Tanosaki, Ryuji, Yamashita, Takuya, Ohwada, Chikako, Kurata, Keiji, Mori, Takeshi, Onozawa, Masahiro, Takano, Kuniko, Yokoyama, Hiroki, Koh, Katsuyoshi, Nagafuji, Koji, Nakayama, Kazutaka, Sakura, Toru, Takahashi, Tsutomu, Oishi, Kazunori, and Fukuda, Takahiro

Published
2023
Full Text
View/download PDF

10. Follow-up of patients with R/R FLT3-mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial

Author

Perl, Alexander E., Larson, Richard A., Podoltsev, Nikolai A., Strickland, Stephen, Wang, Eunice S., Atallah, Ehab, Schiller, Gary J., Martinelli, Giovanni, Neubauer, Andreas, Sierra, Jorge, Montesinos, Pau, Récher, Christian, Yoon, Sung-Soo, Hosono, Naoko, Onozawa, Masahiro, Chiba, Shigeru, Kim, Hee-Je, Hasabou, Nahla, Lu, Qiaoyang, Tiu, Ramon, and Levis, Mark J.

Published
2022
Full Text
View/download PDF

11. Serum IL-1β predicts de novo hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C, not during anti-cancer/immunosuppressive therapy

Author

Kawagishi, Naoki, Suda, Goki, Sakamori, Ryotaro, Matsui, Takeshi, Onozawa, Masahiro, Yang, Zijian, Yoshida, Sonoe, Ohara, Masatsugu, Kimura, Megumi, Kubo, Akinori, Maehara, Osamu, Fu, Qingjie, Hosoda, Shunichi, Tokuchi, Yoshimasa, Suzuki, Kazuharu, Nakai, Masato, Sho, Takuya, Morikawa, Kenichi, Natsuizaka, Mitsuteru, Ogawa, Koji, Sakai, Hajime, Ohnishi, Shunsuke, Baba, Masaru, Takehara, Tetsuo, and Sakamoto, Naoya

Published
2022
Full Text
View/download PDF

12. High CRP-albumin ratio predicts poor prognosis in transplant ineligible elderly patients with newly diagnosed acute myeloid leukemia

Author

Senjo, Hajime, Onozawa, Masahiro, Hidaka, Daisuke, Yokoyama, Shota, Yamamoto, Satoshi, Tsutsumi, Yutaka, Haseyama, Yoshihito, Nagashima, Takahiro, Mori, Akio, Ota, Shuichi, Sakai, Hajime, Ishihara, Toshimichi, Miyagishima, Takuto, Kakinoki, Yasutaka, Kurosawa, Mitsutoshi, Kobayashi, Hajime, Iwasaki, Hiroshi, Hashimoto, Daigo, Kondo, Takeshi, and Teshima, Takanori

Published
2022
Full Text
View/download PDF

13. Outcomes of Cessation of Nucleos(t)ide Analog Administration on Hepatitis B Virus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation: A Nationwide Retrospective Study

Author

Onozawa, Masahiro, Kusumoto, Shigeru, Najima, Yuho, Hashimoto, Hiroya, Okada, Kohei, Tamaki, Masaharu, Tanaka, Masatsugu, Sato, Takayuki, Takahashi, Tsutomu, Hatano, Kaoru, Onodera, Koichi, Moriuchi, Yukiyoshi, Yakushijin, Kimikazu, Kanda, Junya, Nagafuji, Koji, Ogata, Masao, Nakano, Nobuaki, Tamori, Akihiro, and Mizokami, Masashi

Published
2024
Full Text
View/download PDF

15. Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3

Author

Levis, M, Hamadani, M, Logan, B, Jones, R, Singh, A, Litzow, M, Wingard, J, Papadopoulos, E, Perl, A, Soiffer, R, Ustun, C, Ueda Oshima, M, Uy, G, Waller, E, Vasu, S, Solh, M, Mishra, A, Muffly, L, Kim, H, Mikesch, J, Najima, Y, Onozawa, M, Thomson, K, Nagler, A, Wei, A, Marcucci, G, Geller, N, Hasabou, N, Delgado, D, Rosales, M, Hill, J, Gill, S, Nuthethi, R, King, D, Wittsack, H, Mendizabal, A, Devine, S, Horowitz, M, Chen, Y, Agura, E, Altman, J, Anagnostopoulos, A, Anand, S, Artz, A, Aulitzky, W, Balderman, S, Ballen, K, Becker, M, Beguin, Y, Berkahn, L, Berneman, Z, Bhatt, V, Bilmon, I, Bonifazi, F, Briggs, A, Bruno, B, Brunstein, C, Byrne, M, Byrne, J, Cabrero, M, Cairoli, R, Carrum, G, Cerny, J, Cheong, J, Ciceri, F, Colorado, M, Cook, R, Couriel, D, Craddock, C, Damon, L, Deol, A, Desbrosses, Y, Di Grazia, C, Di Stasi, A, Dias, A, Dorritie, K, Essell, J, Eto, T, Farag, S, Forcade, E, Frankfurt, O, Fujiwara, S, Fukuda, T, Fukushima, K, Furst, S, Goto, T, Hall, A, Hatta, S, Hicheri, Y, Horwitz, M, Hou, H, How, J, Howard, D, Hsu, W, Huynh, A, Irvine, D, Ishikawa, T, Jamieson, K, Jedrzejczak, W, Jethava, Y, Jimenez, A, Jung, C, Kanda, J, Karakasis, D, Kato, J, Kekre, N, Khera, N, Klein, A, Kobbe, G, Kornblit, B, Kota, V, Lachance, S, Leber, B, Lee, C, Lee, J, Lin, T, Liu, T, Martelli, M, Martinez, C, Matsuoka, K, Mccarty, J, Mendez, L, Michelis, F, Mineishi, S, Mohty, M, Moors, I, Motyckova, G, Mueller, L, Nakamae, H, Nakano, N, Nathan, S, Nicholson, E, Norkin, M, Ogawa, Y, Olesen, G, Oluwole, O, Pantin, J, Paulson, K, Pemberton, L, Perera, T, Piatkowska-Jakubas, B, Poire, X, Protheroe, R, Rambaldi, A, Ritchie, D, Ross, K, Rubio, M, Santarone, S, Sanz Caballer, J, Sawa, M, Schaar, D, Scheid, C, Schriber, J, Seropian, S, Shah, N, Shore, T, Gil, J, Sobecks, R, Socie, G, Sprague, K, Spyridonidis, A, Stelljes, M, Stiff, P, Stuart, R, Tanaka, M, Tandra, A, Tholouli, E, Thomas, X, Tiribelli, M, Tomlinson, B, Tsirigotis, P, Tzachanis, D, Uchida, N, Ueda, M, Valcarcel Ferreiras, D, Wagner, E, Watson, A, Weisdorf, D, Wolschke, C, Wrobel, T, Yakoub-Agha, I, Yamauchi, T, Yared, J, Yeh, S, Yoon, S, Yoshihara, S, Null, N, Levis, Mark J., Hamadani, Mehdi, Logan, Brent, Jones, Richard J., Singh, Anurag K., Litzow, Mark, Wingard, John R., Papadopoulos, Esperanza B., Perl, Alexander E., Soiffer, Robert J., Ustun, Celalettin, Ueda Oshima, Masumi, Uy, Geoffrey L., Waller, Edmund K., Vasu, Sumithra, Solh, Melhem, Mishra, Asmita, Muffly, Lori, Kim, Hee-Je, Mikesch, Jan-Henrik, Najima, Yuho, Onozawa, Masahiro, Thomson, Kirsty, Nagler, Arnon, Wei, Andrew H., Marcucci, Guido, Geller, Nancy L., Hasabou, Nahla, Delgado, David, Rosales, Matt, Hill, Jason, Gill, Stanley C., Nuthethi, Rishita, King, Denise, Wittsack, Heather, Mendizabal, Adam, Devine, Steven M., Horowitz, Mary M., Chen, Yi-Bin, Agura, Ed, Altman, Jessica, Anagnostopoulos, Achiles, Anand, Sarah, Artz, Andrew, Aulitzky, Walter, Balderman, Sophia, Ballen, Karen, Becker, Michael, Beguin, Yves, Berkahn, Leanne, Berneman, Zwi, Bhatt, Vijaya, Bilmon, Ian, Bonifazi, Francesca, Briggs, Adrienne, Bruno, Benedetto, Brunstein, Claudio, Byrne, Michael, Byrne, Jenny, Cabrero, Monica, Cairoli, Roberto, Carrum, George, Cerny, Jan, Cheong, June-Won, Ciceri, Fabio, Colorado, Mercedes, Cook, Rachel, Couriel, Daniel, Craddock, Charles, Damon, Lloyd, Deol, Abhinav, Desbrosses, Yohan, Devine, Steve, Di Grazia, Carmela, Di Stasi, Antonio, Dias, Ajoy, Dorritie, Kathy, Essell, James, Eto, Tetsuya, Farag, Sherif, Forcade, Edouard, Frankfurt, Olga, Fujiwara, Shinichiro, Fukuda, Takahiro, Fukushima, Kentaro, Furst, Sabine, Goto, Tatsunori, Hall, Aric, Hatta, Shunsuke, Hicheri, Yosr, Horwitz, Mitchell, Hou, Hsin-An, How, Jonathan, Howard, Dianna, Hsu, Wei-Hsun (Blake), Huynh, Anne, Irvine, David, Ishikawa, Takayuki, Jamieson, Katarzyna, Jedrzejczak, Wieslaw, Jethava, Yogesh, Jimenez, Antonio, Jung, Chul Won, Kanda, Junya, Karakasis, Dimitrios, Kato, Jun, Kekre, Natasha, Khera, Nandita, Klein, Andreas, Kobbe, Guido, Kornblit, Brian, Kota, Vamsi, Lachance, Silvy, Leber, Brian, Lee, Catherine, Lee, Je Hwan, Lin, Tung-Liang, Liu, Ta-Chih, Martelli, Maurizio, Martinez, Carmen, Matsuoka, Kenichi, McCarty, John, Mendez, Lourdes, Michelis, Fotios, Mineishi, Shin, Mohty, Mohamad, Moors, Ine, Motyckova, Gabriela, Mueller, Lutz, Nakamae, Hirohisa, Nakano, Nobuaki, Nathan, Sunita, Nicholson, Emma, Norkin, Maxim, Ogawa, Yoshiaki, Olesen, Gitte, Oluwole, Olalekan, Pantin, Jeremy, Paulson, Kristjan, Pemberton, Lucy, Perera, Travis, Piatkowska-Jakubas, Beata, Poire, Xavier, Protheroe, Rachel, Rambaldi, Alessandro, Ritchie, David, Ross, Kelly, Rubio, Marie-Therese, Santarone, Stella, Sanz Caballer, Jaime, Sawa, Masashi, Schaar, Dale, Scheid, Christoph, Schriber, Jeffrey, Seropian, Stuart, Shah, Nilay, Shah, Nirav, Shore, Tsiporah, Gil, Jorge Sierra, Singh, Anurag, Sobecks, Ronald, Socie, Gerard, Soiffer, Robert, Sprague, Kellie, Spyridonidis, Alexandros, Stelljes, Matthias, Stiff, Patrick, Stuart, Robert, Tanaka, Masatsugu, Tandra, Anand, Tholouli, Eleni, Thomas, Xavier, Tiribelli, Mario, Tomlinson, Benjamin, Tsirigotis, Panagiotis, Tzachanis, Dimitrios, Uchida, Naoyuki, Ueda, Masumi, Valcarcel Ferreiras, David, Wagner, Eva, Watson, Anne-Marie, Weisdorf, Daniel, Wolschke, Christine, Wrobel, Tomasz, Yakoub-Agha, Ibrahim, Yamauchi, Takuji, Yared, Jean, Yeh, Su-Peng, Yoon, Sung-Soo, Yoshihara, Satoshi, null, null, Levis, M, Hamadani, M, Logan, B, Jones, R, Singh, A, Litzow, M, Wingard, J, Papadopoulos, E, Perl, A, Soiffer, R, Ustun, C, Ueda Oshima, M, Uy, G, Waller, E, Vasu, S, Solh, M, Mishra, A, Muffly, L, Kim, H, Mikesch, J, Najima, Y, Onozawa, M, Thomson, K, Nagler, A, Wei, A, Marcucci, G, Geller, N, Hasabou, N, Delgado, D, Rosales, M, Hill, J, Gill, S, Nuthethi, R, King, D, Wittsack, H, Mendizabal, A, Devine, S, Horowitz, M, Chen, Y, Agura, E, Altman, J, Anagnostopoulos, A, Anand, S, Artz, A, Aulitzky, W, Balderman, S, Ballen, K, Becker, M, Beguin, Y, Berkahn, L, Berneman, Z, Bhatt, V, Bilmon, I, Bonifazi, F, Briggs, A, Bruno, B, Brunstein, C, Byrne, M, Byrne, J, Cabrero, M, Cairoli, R, Carrum, G, Cerny, J, Cheong, J, Ciceri, F, Colorado, M, Cook, R, Couriel, D, Craddock, C, Damon, L, Deol, A, Desbrosses, Y, Di Grazia, C, Di Stasi, A, Dias, A, Dorritie, K, Essell, J, Eto, T, Farag, S, Forcade, E, Frankfurt, O, Fujiwara, S, Fukuda, T, Fukushima, K, Furst, S, Goto, T, Hall, A, Hatta, S, Hicheri, Y, Horwitz, M, Hou, H, How, J, Howard, D, Hsu, W, Huynh, A, Irvine, D, Ishikawa, T, Jamieson, K, Jedrzejczak, W, Jethava, Y, Jimenez, A, Jung, C, Kanda, J, Karakasis, D, Kato, J, Kekre, N, Khera, N, Klein, A, Kobbe, G, Kornblit, B, Kota, V, Lachance, S, Leber, B, Lee, C, Lee, J, Lin, T, Liu, T, Martelli, M, Martinez, C, Matsuoka, K, Mccarty, J, Mendez, L, Michelis, F, Mineishi, S, Mohty, M, Moors, I, Motyckova, G, Mueller, L, Nakamae, H, Nakano, N, Nathan, S, Nicholson, E, Norkin, M, Ogawa, Y, Olesen, G, Oluwole, O, Pantin, J, Paulson, K, Pemberton, L, Perera, T, Piatkowska-Jakubas, B, Poire, X, Protheroe, R, Rambaldi, A, Ritchie, D, Ross, K, Rubio, M, Santarone, S, Sanz Caballer, J, Sawa, M, Schaar, D, Scheid, C, Schriber, J, Seropian, S, Shah, N, Shore, T, Gil, J, Sobecks, R, Socie, G, Sprague, K, Spyridonidis, A, Stelljes, M, Stiff, P, Stuart, R, Tanaka, M, Tandra, A, Tholouli, E, Thomas, X, Tiribelli, M, Tomlinson, B, Tsirigotis, P, Tzachanis, D, Uchida, N, Ueda, M, Valcarcel Ferreiras, D, Wagner, E, Watson, A, Weisdorf, D, Wolschke, C, Wrobel, T, Yakoub-Agha, I, Yamauchi, T, Yared, J, Yeh, S, Yoon, S, Yoshihara, S, Null, N, Levis, Mark J., Hamadani, Mehdi, Logan, Brent, Jones, Richard J., Singh, Anurag K., Litzow, Mark, Wingard, John R., Papadopoulos, Esperanza B., Perl, Alexander E., Soiffer, Robert J., Ustun, Celalettin, Ueda Oshima, Masumi, Uy, Geoffrey L., Waller, Edmund K., Vasu, Sumithra, Solh, Melhem, Mishra, Asmita, Muffly, Lori, Kim, Hee-Je, Mikesch, Jan-Henrik, Najima, Yuho, Onozawa, Masahiro, Thomson, Kirsty, Nagler, Arnon, Wei, Andrew H., Marcucci, Guido, Geller, Nancy L., Hasabou, Nahla, Delgado, David, Rosales, Matt, Hill, Jason, Gill, Stanley C., Nuthethi, Rishita, King, Denise, Wittsack, Heather, Mendizabal, Adam, Devine, Steven M., Horowitz, Mary M., Chen, Yi-Bin, Agura, Ed, Altman, Jessica, Anagnostopoulos, Achiles, Anand, Sarah, Artz, Andrew, Aulitzky, Walter, Balderman, Sophia, Ballen, Karen, Becker, Michael, Beguin, Yves, Berkahn, Leanne, Berneman, Zwi, Bhatt, Vijaya, Bilmon, Ian, Bonifazi, Francesca, Briggs, Adrienne, Bruno, Benedetto, Brunstein, Claudio, Byrne, Michael, Byrne, Jenny, Cabrero, Monica, Cairoli, Roberto, Carrum, George, Cerny, Jan, Cheong, June-Won, Ciceri, Fabio, Colorado, Mercedes, Cook, Rachel, Couriel, Daniel, Craddock, Charles, Damon, Lloyd, Deol, Abhinav, Desbrosses, Yohan, Devine, Steve, Di Grazia, Carmela, Di Stasi, Antonio, Dias, Ajoy, Dorritie, Kathy, Essell, James, Eto, Tetsuya, Farag, Sherif, Forcade, Edouard, Frankfurt, Olga, Fujiwara, Shinichiro, Fukuda, Takahiro, Fukushima, Kentaro, Furst, Sabine, Goto, Tatsunori, Hall, Aric, Hatta, Shunsuke, Hicheri, Yosr, Horwitz, Mitchell, Hou, Hsin-An, How, Jonathan, Howard, Dianna, Hsu, Wei-Hsun (Blake), Huynh, Anne, Irvine, David, Ishikawa, Takayuki, Jamieson, Katarzyna, Jedrzejczak, Wieslaw, Jethava, Yogesh, Jimenez, Antonio, Jung, Chul Won, Kanda, Junya, Karakasis, Dimitrios, Kato, Jun, Kekre, Natasha, Khera, Nandita, Klein, Andreas, Kobbe, Guido, Kornblit, Brian, Kota, Vamsi, Lachance, Silvy, Leber, Brian, Lee, Catherine, Lee, Je Hwan, Lin, Tung-Liang, Liu, Ta-Chih, Martelli, Maurizio, Martinez, Carmen, Matsuoka, Kenichi, McCarty, John, Mendez, Lourdes, Michelis, Fotios, Mineishi, Shin, Mohty, Mohamad, Moors, Ine, Motyckova, Gabriela, Mueller, Lutz, Nakamae, Hirohisa, Nakano, Nobuaki, Nathan, Sunita, Nicholson, Emma, Norkin, Maxim, Ogawa, Yoshiaki, Olesen, Gitte, Oluwole, Olalekan, Pantin, Jeremy, Paulson, Kristjan, Pemberton, Lucy, Perera, Travis, Piatkowska-Jakubas, Beata, Poire, Xavier, Protheroe, Rachel, Rambaldi, Alessandro, Ritchie, David, Ross, Kelly, Rubio, Marie-Therese, Santarone, Stella, Sanz Caballer, Jaime, Sawa, Masashi, Schaar, Dale, Scheid, Christoph, Schriber, Jeffrey, Seropian, Stuart, Shah, Nilay, Shah, Nirav, Shore, Tsiporah, Gil, Jorge Sierra, Singh, Anurag, Sobecks, Ronald, Socie, Gerard, Soiffer, Robert, Sprague, Kellie, Spyridonidis, Alexandros, Stelljes, Matthias, Stiff, Patrick, Stuart, Robert, Tanaka, Masatsugu, Tandra, Anand, Tholouli, Eleni, Thomas, Xavier, Tiribelli, Mario, Tomlinson, Benjamin, Tsirigotis, Panagiotis, Tzachanis, Dimitrios, Uchida, Naoyuki, Ueda, Masumi, Valcarcel Ferreiras, David, Wagner, Eva, Watson, Anne-Marie, Weisdorf, Daniel, Wolschke, Christine, Wrobel, Tomasz, Yakoub-Agha, Ibrahim, Yamauchi, Takuji, Yared, Jean, Yeh, Su-Peng, Yoon, Sung-Soo, Yoshihara, Satoshi, and null, null

Abstract

PURPOSEAllogeneic hematopoietic cell transplantation (HCT) improves outcomes for patients with AML harboring an internal tandem duplication mutation of FLT3 (FLT3-ITD) AML. These patients are routinely treated with a FLT3 inhibitor after HCT, but there is limited evidence to support this. Accordingly, we conducted a randomized trial of post-HCT maintenance with the FLT3 inhibitor gilteritinib (ClinicalTrials.gov identifier: NCT02997202) to determine if all such patients benefit or if detection of measurable residual disease (MRD) could identify those who might benefit.METHODSAdults with FLT3-ITD AML in first remission underwent HCT and were randomly assigned to placebo or 120 mg once daily gilteritinib for 24 months after HCT. The primary end point was relapse-free survival (RFS). Secondary end points included overall survival (OS) and the effect of MRD pre- and post-HCT on RFS and OS.RESULTSThree hundred fifty-six participants were randomly assigned post-HCT to receive gilteritinib or placebo. Although RFS was higher in the gilteritinib arm, the difference was not statistically significant (hazard ratio [HR], 0.679 [95% CI, 0.459 to 1.005]; two-sided P =.0518). However, 50.5% of participants had MRD detectable pre- or post-HCT, and, in a prespecified subgroup analysis, gilteritinib was beneficial in this population (HR, 0.515 [95% CI, 0.316 to 0.838]; P =.0065). Those without detectable MRD showed no benefit (HR, 1.213 [95% CI, 0.616 to 2.387]; P =.575).CONCLUSIONAlthough the overall improvement in RFS was not statistically significant, RFS was higher for participants with detectable FLT3-ITD MRD pre- or post-HCT who received gilteritinib treatment. To our knowledge, these data are among the first to support the effectiveness of MRD-based post-HCT therapy.

Published
2024

17. Acute onset of constrictive pericarditis due to acute myelomonocytic leukemia: A case and literature review

Author

Kosaka, Naoki, primary, Uchiyama, Takanori, additional, Onozawa, Masahiro, additional, Nagai, Jun, additional, Koya, Jiro, additional, Ishizaka, Suguru, additional, Nagai, Toshiyuki, additional, Ikebe, Yohei, additional, Kato, Kenjiro, additional, Tanei, Zen-ichi, additional, Sakakibara-Konishi, Jun, additional, Hasegawa, Yuta, additional, Ohigashi, Hiroyuki, additional, Goto, Hideki, additional, Hashimoto, Daigo, additional, Ujiie, Hideki, additional, Hirano, Satoshi, additional, Konno, Satoshi, additional, Anzai, Toshihisa, additional, Taniguchi, Koji, additional, Tanaka, Shinya, additional, and Teshima, Takanori, additional

Published
2024
Full Text
View/download PDF

24. Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas

Author

Kataoka, Keisuke, Miyoshi, Hiroaki, Sakata, Seiji, Dobashi, Akito, Couronné, Lucile, Kogure, Yasunori, Sato, Yasuharu, Nishida, Kenji, Gion, Yuka, Shiraishi, Yuichi, Tanaka, Hiroko, Chiba, Kenichi, Watatani, Yosaku, Kakiuchi, Nobuyuki, Shiozawa, Yusuke, Yoshizato, Tetsuichi, Yoshida, Kenichi, Makishima, Hideki, Sanada, Masashi, Onozawa, Masahiro, Teshima, Takanori, Yoshiki, Yumiko, Ishida, Tadao, Suzuki, Kenshi, Shimada, Kazuyuki, Tomita, Akihiro, Kato, Motohiro, Ota, Yasunori, Izutsu, Koji, Demachi-Okamura, Ayako, Akatsuka, Yoshiki, Miyano, Satoru, Yoshino, Tadashi, Gaulard, Philippe, Hermine, Olivier, Takeuchi, Kengo, Ohshima, Koichi, and Ogawa, Seishi

Published
2019
Full Text
View/download PDF

25. P1526: THE RISK OF DEVELOPING PNEUMOCYSTIS JIROVECII PNEUMONIA PERSISTS EVEN AFTER COMPLETION OF IMMUNOSUPPRESSANTS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS

Author

Ara, Takahide, primary, Yokoyama, Shota, additional, Hasegawa, Yuta, additional, Ohigashi, Hiroyuki, additional, Matsukawa, Toshihiro, additional, Yasumoto, Atushi, additional, Shiratori, Souichi, additional, Goto, Hideki, additional, Onozawa, Masahiro, additional, Nakagawa, Masao, additional, Kahata, Kaoru, additional, Endo, Tomoyuki, additional, Hashimoto, Daigo, additional, and Teshima, Takanori, additional

Published
2023
Full Text
View/download PDF

26. P1414: CRP IS A CONVENIENT PREDICTIVE MARKER OF THE ANTIPYRETIC EFFECT OF TOCILIZUMAB ON CRS DURING CAR-T CELL THERAPY

Author

Yokoyama, Shota, primary, Ara, Takahide, additional, Harada, Shinpei, additional, Mori, Yuto, additional, Hasegawa, Yuta, additional, Ohigashi, Hiroyuki, additional, Matsukawa, Toshihiro, additional, Yasumoto, Atsushi, additional, Shiratori, Souichi, additional, Onozawa, Masahiro, additional, Nakagawa, Masao, additional, Kahata, Kaoru, additional, Endo, Tomoyuki, additional, Hashimoto, Daigo, additional, Goto, Hideki, additional, and Teshima, Takanori, additional

Published
2023
Full Text
View/download PDF

27. A novel nutritional index “simplified CONUT” and the disease risk index independently stratify prognosis of elderly patients with acute myeloid leukemia

Author

Senjo, Hajime, Onozawa, Masahiro, Hidaka, Daisuke, Yokoyama, Shota, Yamamoto, Satoshi, Tsutsumi, Yutaka, Haseyama, Yoshihito, Nagashima, Takahiro, Mori, Akio, Ota, Shuichi, Sakai, Hajime, Ishihara, Toshimichi, Miyagishima, Takuto, Kakinoki, Yasutaka, Kurosawa, Mitsutoshi, Kobayashi, Hajime, Iwasaki, Hiroshi, Hashimoto, Daigo, Kondo, Takeshi, and Teshima, Takanori

Published
2020
Full Text
View/download PDF

29. Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT

Author

Noviello, Maddalena, Manfredi, Francesco, Ruggiero, Eliana, Perini, Tommaso, Oliveira, Giacomo, Cortesi, Filippo, De Simone, Pantaleo, Toffalori, Cristina, Gambacorta, Valentina, Greco, Raffaella, Peccatori, Jacopo, Casucci, Monica, Casorati, Giulia, Dellabona, Paolo, Onozawa, Masahiro, Teshima, Takanori, Griffioen, Marieke, Halkes, Constantijn J. M., Falkenburg, J. H. F., Stölzel, Friedrich, Altmann, Heidi, Bornhäuser, Martin, Waterhouse, Miguel, Zeiser, Robert, Finke, Jürgen, Cieri, Nicoletta, Bondanza, Attilio, Vago, Luca, Ciceri, Fabio, and Bonini, Chiara

Published
2019
Full Text
View/download PDF

30. Subclinical minute FLT3-ITD clone can be detected in clinically FLT3-ITD-negative acute myeloid leukaemia at diagnosis

Author

Yokoyama, Shota, Onozawa, Masahiro, Yoshida, Shota, Miyashita, Naoki, Kimura, Hiroyuki, Takahashi, Shogo, Matsukawa, Toshihiro, Goto, Hideki, Fujisawa, Shinichi, Miki, Kosuke, Hidaka, Daisuke, Hashiguchi, Junichi, Wakasa, Kentaro, Ibata, Makoto, Takeda, Yukari, Shigematsu, Akio, Fujimoto, Katsuya, Tsutsumi, Yutaka, Mori, Akio, Ishihara, Toshimichi, Kakinoki, Yasutaka, Kondo, Takeshi, Hashimoto, Daigo, Teshima, Takanori, Yokoyama, Shota, Onozawa, Masahiro, Yoshida, Shota, Miyashita, Naoki, Kimura, Hiroyuki, Takahashi, Shogo, Matsukawa, Toshihiro, Goto, Hideki, Fujisawa, Shinichi, Miki, Kosuke, Hidaka, Daisuke, Hashiguchi, Junichi, Wakasa, Kentaro, Ibata, Makoto, Takeda, Yukari, Shigematsu, Akio, Fujimoto, Katsuya, Tsutsumi, Yutaka, Mori, Akio, Ishihara, Toshimichi, Kakinoki, Yasutaka, Kondo, Takeshi, Hashimoto, Daigo, and Teshima, Takanori

Abstract

Recent advances in next-generation sequencing (NGS) have enabled the detection of subclinical minute FLT3-ITD. We selected 74 newly diagnosed, cytogenetically normal acute myeloid leukaemia (AML) samples in which FLT3-ITD was not detected by gel electrophoresis. We sequenced them using NGS and found minute FLT3-ITDs in 19 cases. We compared cases with clinically relevant FLT3-ITD (n = 37), cases with minute FLT3-ITD (n = 19) and cases without detectable FLT3-ITD (n = 55). Molecular characteristics (location and length) of minute FLT3-ITD were similar to those of clinically relevant FLT3-ITD. Survival of cases with minute FLT3-ITD was similar to that of cases without detectable FLT3-ITD, whereas the relapse rate within 1 year after onset was significantly higher in cases with minute FLT3-ITD. We followed 18 relapsed samples of cases with clinically FLT3-ITD-negative at diagnosis. Two of 3 cases with minute FLT3-ITD relapsed with progression to clinically relevant FLT3-ITD. Two of 15 cases in which FLT3-ITD was not detected by NGS relapsed with the emergence of minute FLT3-ITD, and one of them showed progression to clinically relevant FLT3-ITD at the second relapse. We revealed the clonal dynamics of subclinical minute FLT3-ITD in clinically FLT3-ITD-negative AML. Minute FLT3-ITD at the initial AML can expand to become a dominant clone at relapse.

Published
2023

31. Prognostic impact of FLT3-ITD, NPM1 mutation and CEBPA bZIP domain mutation in cytogenetically normal acute myeloid leukemia : a Hokkaido Leukemia Net study

Author

Miyashita, Naoki, Onozawa, Masahiro, Yoshida, Shota, Kimura, Hiroyuki, Takahashi, Shogo, Yokoyama, Shota, Matsukawa, Toshihiro, Hirabayashi, Shinsuke, Fujisawa, Shinichi, Mori, Akio, Ota, Shuichi, Kakinoki, Yasutaka, Tsutsumi, Yutaka, Yamamoto, Satoshi, Miyagishima, Takuto, Nagashima, Takahiro, Ibata, Makoto, Wakasa, Kentaro, Haseyama, Yoshihito, Fujimoto, Katsuya, Ishihara, Toshimichi, Sakai, Hajime, Kondo, Takeshi, Teshima, Takanori, Miyashita, Naoki, Onozawa, Masahiro, Yoshida, Shota, Kimura, Hiroyuki, Takahashi, Shogo, Yokoyama, Shota, Matsukawa, Toshihiro, Hirabayashi, Shinsuke, Fujisawa, Shinichi, Mori, Akio, Ota, Shuichi, Kakinoki, Yasutaka, Tsutsumi, Yutaka, Yamamoto, Satoshi, Miyagishima, Takuto, Nagashima, Takahiro, Ibata, Makoto, Wakasa, Kentaro, Haseyama, Yoshihito, Fujimoto, Katsuya, Ishihara, Toshimichi, Sakai, Hajime, Kondo, Takeshi, and Teshima, Takanori

Abstract

Mutation status of FLT3, NPM1, and CEBPA is used to classify the prognosis of acute myeloid leukemia, but its significance in patients with cytogenetically normal (CN) AML is unclear. We prospectively analyzed these genes in 295 patients with CN-AML and identified 76 (25.8%) FLT3-ITD, 113 (38.3%) NPM1 mutations, and 30 (10.2%) CEBPA biallelic mutations. We found that patients with FLT3-ITD had a poor prognosis at any age, while patients with CEBPA biallelic mutation were younger and had a better prognosis. FLT3-ITD and NPM1 mutations were correlated, and the favorable prognostic impact of being FLT3-ITD negative and NPM1 mutation positive was evident only in patients aged 65 years or more. For CEBPA, 86.7% of the patients with biallelic mutation and 9.1% of patients with the single allele mutation had in-frame mutations in the bZIP domain, which were strongly associated with a favorable prognosis. Multivariate analysis showed that age < 65 years, FLT3-ITD and CEBPA bZIP in-frame mutation were independent prognostic factors. The results suggest that analyzing these gene mutations at diagnosis can inform selection of the optimal intensity of therapy for patients with CN-AML.

Published
2023

32. Prognostic factors in patients in the terminal phase of haematological malignancies who are receiving home medical care

Author

Miyashita, Naohiro, Ohashi, Kota, Fujita, Mariko, Hosoda, Toru, Kawasaki, Yasufumi, Takimoto, Madoka, 1000070455632, Onozawa, Masahiro, Miyashita, Naohiro, Ohashi, Kota, Fujita, Mariko, Hosoda, Toru, Kawasaki, Yasufumi, Takimoto, Madoka, 1000070455632, and Onozawa, Masahiro

Abstract

Although there are many prognostic models for patients in the terminal phase of solid tumours, a reliable prognostic scoring system in patients in the terminal phase of haematological malignancies (HM) has not been established. We retrospectively evaluated 180 patients in the terminal phase of HM who were receiving home medical care (HMC). Multivariate analyses revealed that clinician's estimate, consciousness, loss of appetite, dyspnoea, neutrophil count, lymphocyte count, and lactate dehydrogenase were associated with overall survival (OS). Based on this result, we developed a novel prognostic scoring system, the Japan palliative haematological oncology prognostic estimates, in which four risk groups were shown to clearly differ in survival (p < 0.001): a low-risk group (n = 41, median OS of 434 days), an intermediate-low-risk group (n = 80, median OS of 112 days), an intermediate-high-risk group (n = 38, median OS of 31.5 days), and a high-risk group (n = 21, median OS of 10 days). This is the first investigation of prognostic factors that influence the OS of patients in the terminal phase of HM who are receiving HMC. Providing patients with reliable information about their prognosis is important for them to consider how to spend their remaining life.

Published
2023

33. Clinical features of complex karyotype in newly diagnosed acute myeloid leukemia

Author

Yoshida, Shota, Onozawa, Masahiro, Miyashita, Naoki, Kimura, Hiroyuki, Takahashi, Shogo, Yokoyama, Shota, Matsukawa, Toshihiro, Hirabayashi, Shinsuke, Mori, Akio, Hidaka, Daisuke, Minauchi, Koichiro, Shigematsu, Akio, Hashiguchi, Junichi, Igarashi, Tetsuyuki, Kakinoki, Yasutaka, Tsutsumi, Yutaka, Ibata, Makoto, Kobayashi, Hajime, Haseyama, Yoshihito, Fujimoto, Katsuya, Ishihara, Toshimichi, Sakai, Hajime, Ota, Shuichi, Kondo, Takeshi, Teshima, Takanori, Yoshida, Shota, Onozawa, Masahiro, Miyashita, Naoki, Kimura, Hiroyuki, Takahashi, Shogo, Yokoyama, Shota, Matsukawa, Toshihiro, Hirabayashi, Shinsuke, Mori, Akio, Hidaka, Daisuke, Minauchi, Koichiro, Shigematsu, Akio, Hashiguchi, Junichi, Igarashi, Tetsuyuki, Kakinoki, Yasutaka, Tsutsumi, Yutaka, Ibata, Makoto, Kobayashi, Hajime, Haseyama, Yoshihito, Fujimoto, Katsuya, Ishihara, Toshimichi, Sakai, Hajime, Ota, Shuichi, Kondo, Takeshi, and Teshima, Takanori

Abstract

Complex karyotype acute myeloid leukemia (CK-AML) has been classified as an adverse-risk subtype. Although a few reports have further classified CK-AML as typical (including monosomy of chromosomes 5, 7 and 17 or deletion of 5q, 7q and/or 17p) or atypical, the clinical features of these subtypes in Japanese patients remain unclear. We retrospectively analyzed a total of 115 patients with CK-AML, including 77 with typical CK-AML and 38 with atypical CK-AML. Median overall survival (OS) was significantly shorter in patients with typical CK-AML than atypical CK-AML (143 days vs. 369 days, P = 0.009). Among patients with typical CK-AML, those with monosomy 17 or deletion of 17p had significantly shorter OS than patients without such abnormalities (105 days vs. 165 days, P = 0.033). TP53 mutations were more predominant in patients with typical CK-AML than in patients with atypical CK-AML (69.7% vs. 32.4%, P < 0.001). Patients with typical CK-AML had a poor prognosis regardless of TP53 mutation status. Among patients with atypical CK-AML, however, prognosis was worse for those with the TP53 mutation than those without the mutation. In conclusion, prognosis is extremely poor for both typical CK-AML and atypical CK-AML with TP53 mutation.

Published
2023

36. Fatal case of subdural empyema caused by Campylobacter rectus and Slackia exigua

Author

Munekata, Yuki, primary, Yamamoto, Saki, additional, Kato, Shun, additional, Kitagawa, Yutaro, additional, Enda, Ken, additional, Okazaki, Nanase, additional, Tanikawa, Satoshi, additional, Tanei, Zen-ichi, additional, Ikebe, Yohei, additional, Osawa, Takahiro, additional, Takamiya, Soichiro, additional, Ujiie, Hideki, additional, Onozawa, Masahiro, additional, Hirano, Satoshi, additional, Fujimura, Miki, additional, and Tanaka, Shinya, additional

Published
2023
Full Text
View/download PDF

37. Subcutaneous Panniculitis-like T-cell Lymphoma Lacking Subcutaneous Tumor Mimicking Adult-onset Still's Disease

Author

Tada, Maria, primary, Kachi, Shion, additional, Onozawa, Masahiro, additional, Fujieda, Yuichiro, additional, Yoshida, Shota, additional, Oki, Yotaro, additional, Kamada, Kazuro, additional, Nagai, Jun, additional, Okada, Satomi, additional, Kikuchi, Ryo, additional, Hisada, Ryo, additional, Hasegawa, Yuta, additional, Ohigashi, Hiroyuki, additional, Goto, Hideki, additional, Hashimoto, Daigo, additional, Nakazato, Shinichi, additional, Matsuno, Yoshihiro, additional, Teshima, Takanori, additional, and Atsumi, Tatsuya, additional

Published
2023
Full Text
View/download PDF

38. Prognostic Impact of CEBPA bZIP Domain Mutation in Cytogenetically Normal Acute Myeloid Leukemia

Author

Miyashita, Naoki, primary, Onozawa, Masahiro, additional, Yoshida, Shota, additional, Kimura, Hiroyuki, additional, Takahashi, Shogo, additional, Yokoyama, Shota, additional, Matsukawa, Toshihiro, additional, Hirabayashi, Shinsuke, additional, Fujisawa, Shinichi, additional, Mori, Akio, additional, Ota, Shuichi, additional, Kakinoki, Yasutaka, additional, Tsutsumi, Yutaka, additional, Yamamoto, Satoshi, additional, Miyagishima, Takuto, additional, Nagashima, Takahiro, additional, Ibata, Makoto, additional, Kobayashi, Hajime, additional, Haseyama, Yoshihito, additional, Fujimoto, Katsuya, additional, Ishihara, Toshimichi, additional, Sakai, Hajime, additional, Kondo, Takeshi, additional, and Teshima, Takanori, additional

Published
2022
Full Text
View/download PDF

39. Clinical Features of Complex Karyotype in Newly Diagnosed Acute Myeloid Leukemia

Author

Yoshida, Shota, primary, Onozawa, Masahiro, additional, Miyashita, Naoki, additional, Kimura, Hiroyuki, additional, Takahashi, Shogo, additional, Yokoyama, Shota, additional, Matsukawa, Toshihiro, additional, Hirabayashi, Shinsuke, additional, Mori, Akio, additional, Kondo, Takeshi, additional, Hidaka, Daisuke, additional, Minauchi, Koichiro, additional, Shigematsu, Akio, additional, Hashiguchi, Junichi, additional, Igarashi, Tetsuyuki, additional, Kakinoki, Yasutaka, additional, Tsutsumi, Yutaka, additional, Iwasaki, Hiroshi, additional, Kobayashi, Hajime, additional, Haseyama, Yoshihito, additional, Fujimoto, Katsuya, additional, Ishihara, Toshimichi, additional, Sakai, Hajime, additional, Iyama, Satoshi, additional, and Teshima, Takanori, additional

Published
2022
Full Text
View/download PDF

40. Better Prognosis of Dominant-Negative Type of IKZF1 Deletion in BCR-ABL-positive Adult B-Cell Acute Lymphoblastic Leukemia

Author

Kimura, Hiroyuki, primary, Onozawa, Masahiro, additional, Yoshida, Shota, additional, Miyashita, Naoki, additional, Takahashi, Shogo, additional, Yokoyama, Shota, additional, Matsukawa, Toshihiro, additional, Hirabayashi, Shinsuke, additional, Fujisawa, Shinichi, additional, Ota, Shuichi, additional, Hidaka, Daisuke, additional, Mori, Akio, additional, Kondo, Takeshi, additional, Kakinoki, Yasutaka, additional, Tsutsumi, Yutaka, additional, Yamamoto, Satoshi, additional, Miyagishima, Takuto, additional, Nagashima, Takahiro, additional, Ibata, Makoto, additional, Kobayashi, Hajime, additional, Haseyama, Yoshihito, additional, Fujimoto, Katsuya, additional, Ishihara, Toshimichi, additional, Sakai, Hajime, additional, and Teshima, Takanori, additional

Published
2022
Full Text
View/download PDF

41. Subclinical Minute FLT3-ITD Clone Can be Detected in Clinically FLT3-ITD-Negative Acute Myeloid Leukemia

Author

Yokoyama, Shota, primary, Onozawa, Masahiro, additional, Yoshida, Shota, additional, Miyashita, Naoki, additional, Kimura, Hiroyuki, additional, Takahashi, Shogo, additional, Matsukawa, Toshihiro, additional, Fujisawa, Shinichi, additional, Miki, Kosuke, additional, Hidaka, Daisuke, additional, Hashiguchi, Junichi, additional, Wakasa, Kentaro, additional, Ibata, Makoto, additional, Takeda, Yukari, additional, Shigematsu, Akio, additional, Fujimoto, Katsuya, additional, Tsutsumi, Yutaka, additional, Mori, Akio, additional, Ishihara, Toshimichi, additional, Kakinoki, Yasutaka, additional, Kondo, Takeshi, additional, and Teshima, Takanori, additional

Published
2022
Full Text
View/download PDF

42. Booster Effect of a Third mRNA-Based COVID-19 Vaccine Dose in Patients with Myeloid Malignancies

Author

Mori, Akio, primary, Onozawa, Masahiro, additional, Kobayashi, Mirei, additional, Tsukamoto, Shihori, additional, Senjo, Hajime, additional, Ishio, Takashi, additional, Yokoyama, Emi, additional, Izumiyama, Koh, additional, Saito, Makoto, additional, Muraki, Haruna, additional, Morioka, Masanobu, additional, Teshima, Takanori, additional, and Kondo, Takeshi, additional

Published
2022
Full Text
View/download PDF

45. Booster effect of a third mRNA‐based COVID‐19 vaccine dose in patients with myeloid malignancies.

Author

Mori, Akio, Onozawa, Masahiro, Kobayashi, Mirei, Tsukamoto, Shihori, Senjo, Hajime, Ishio, Takashi, Yokoyama, Emi, Kanaya, Minoru, Izumiyama, Koh, Saito, Makoto, Muraki, Haruna, Morioka, Masanobu, Teshima, Takanori, and Kondo, Takeshi

Subjects
*MESSENGER RNA, *COVID-19 vaccines, *VACCINE immunogenicity, *ACUTE myeloid leukemia, *BOOSTER vaccines
Abstract

Background: We have reported that seroconversion rates after the second dose of mRNA‐based COVID‐19 vaccines for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) were 100% and 95% respectively, with no significant difference from healthy controls (HCs).However, there are very limited data for the response to a third vaccine dose in those patients. Aims: In this complementary study, we investigated the booster effect of a third mRNA‐based COVID‐19 vaccine dose in patients with myeloid malignancies. Materials & Methods: A total 58 patients including 20 patients with MDS and 38 patients with AML were enrolled. Anti‐SARS‐CoV‐2S immunoassays were performed at 3, 6, and 9 months after the second vaccine dose. Results: Seventy‐five percent of the MDS patients and 37% of the AML patients were receiving active treatment at the time of the third vaccination. Both the initial and third vaccine response in AML patients were comparable to those in HCs. In MDS patients, although the initial vaccine immunogenicity was inferior to that in HCs and AML patients, the third vaccine improved the response to a level not inferior to those in HCs and AML patients. Of note, the third vaccine resulted in a significant increase of antibodies in actively treated MDS patients who had shown a response inferior to that in untreated patients after two doses of vaccination. Discussion: In patients with myeloid malignancies, the third vaccine dose showed a booster effect, and disease‐ and therapy‐related factors associated with the booster response have been identified. Conclusion: The third dose of an mRNA‐based COVID‐19 vaccine showed a booster effect in patients with myeloid malignancies. Such a good booster response has not been reported in other haematological malignancies. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

46. Intestinal Lymphatic Endothelial Cells Produce R-Spondin3

Author

Ogasawara, Reiki, Hashimoto, Daigo, Kimura, Shunsuke, Hayase, Eiko, Ara, Takahide, Takahashi, Shuichiro, Ohigashi, Hiroyuki, Yoshioka, Kosuke, Tateno, Takahiro, Yokoyama, Emi, Ebata, Ko, Kondo, Takeshi, Sugita, Junichi, Onozawa, Masahiro, Iwanaga, Toshihiko, and Teshima, Takanori

Published
2018
Full Text
View/download PDF

47. Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan

Author

Ikezoe, Takayuki, primary, Ando, Kiyoshi, additional, Onozawa, Masahiro, additional, Yamane, Takahisa, additional, Hosono, Naoko, additional, Morita, Yasuyoshi, additional, Kiguchi, Toru, additional, Iwasaki, Hiromi, additional, Miyamoto, Toshihiro, additional, Matsubara, Keisuke, additional, Sugimoto, Saori, additional, Miyazaki, Yasushi, additional, Kizaki, Masahiro, additional, and Akashi, Koichi, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results